UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 4, 2021
FUSION PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
| Canada | 001-39344 | Not Applicable | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| 270 Longwood Road South Hamilton, Ontario, Canada, L8P 0A6 (Address of principal executive offices, including zip code) |
(289) 799-0891
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trade Symbol(s) |
Name of each exchange on which registered | ||
| Common shares, no par value per share | FUSN | The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
Fusion Pharmaceuticals Inc. (the “Company”) held its annual meeting of shareholders on June 4, 2021 (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders voted in the following manner with respect to the following proposals:
| 1. | The election of Directors, each to serve until the 2022 annual meeting of shareholders. The final voting results were as follows: |
| Nominee | For | Against | Abstain | |||||||||
| Donald Bergstrom, M.D., Ph.D. |
19,607,771 | 0 | 9,418 | |||||||||
| Pablo Cagnoni, M.D. |
19,604,489 | 0 | 12,700 | |||||||||
| Johan Christenson, Ph.D. |
19,607,771 | 0 | 9,418 | |||||||||
| Barbara Duncan |
17,243,747 | 0 | 2,373,442 | |||||||||
| Steve Gannon |
19,607,711 | 0 | 9,478 | |||||||||
| Philina Lee, Ph.D. |
19,607,672 | 0 | 9,517 | |||||||||
| Chau Khuong |
19,607,771 | 0 | 9,418 | |||||||||
| Heather Preston, M.D. |
19,568,069 | 0 | 49,120 | |||||||||
| John Valliant, Ph.D. |
19,607,771 | 0 | 9,418 | |||||||||
| 2. | The ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm the current fiscal year ending December 31, 2021 was approved as follows: |
| For: |
23,761,138 | |||
| Against: |
7,085 | |||
| Abstain: |
1,800 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Fusion Pharmaceuticals Inc. | ||||||
| Date: June 7, 2021 | By: | /s/ Maria Stahl | ||||
| Maria Stahl | ||||||
| Chief Legal Officer | ||||||